RxDoctor Payments Data

Gopi Krishna Polasa Venkata, MD

Internal Medicine · Los Banos, CANPI 1295154839

Payments from drug & device makers

$1,588in general payments, 2019–2025

Across 91 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$432
  • Boehringer Ingelheim$232
  • AstraZeneca$174
  • Johnson & Johnson$86
  • Lilly USA, LLC$80
  • Pfizer$80
  • plus $505 from 11 others

What the payments were for

  • Food & beverage$1,588100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,588 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$124,440
Medicare patients
396
Services billed
1,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide171$223,959
JardianceEmpagliflozin131$147,041
MounjaroTirzepatide82$95,129
FarxigaDapagliflozin Propanediol54$54,335
TrulicityDulaglutide37$43,507
EliquisApixaban28$22,869
XareltoRivaroxaban19$22,000
SynjardyEmpagliflozin/Metformin Hcl15$21,514
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog51$18,966
MyrbetriqMirabegron20$16,348
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,328
Tresiba Flextouch U-100Insulin Degludec13$6,967
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$5,618
Atorvastatin Calcium480$5,493
Breo ElliptaFluticasone/Vilanterol11$4,665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$432$223,959171 claims
Boehringer IngelheimJardiance, Synjardy$232$168,554146 claims
Lilly USA, LLCMounjaro, Trulicity$80$138,636119 claims
AstraZenecaFarxiga$174$54,33554 claims
PfizerEliquis$80$22,86928 claims
Johnson & JohnsonXarelto$86$22,00019 claims
Astellas Pharma US IncMyrbetriq$55$16,34820 claims
GSKTrelegy Ellipta, Breo Ellipta$28$11,99422 claims
Sanofi-aventis U.S. LLCLantus$16$2,45824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Banos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →